📣 VC round data is live. Check it out!

Orchestra BioMed Valuation Multiples

Discover revenue and EBITDA valuation multiples for Orchestra BioMed and similar public comparables like Asterasys, Stratec, OraSure, Affluent Medical and more.

Orchestra BioMed Overview

About Orchestra BioMed

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.


Founded

2018

HQ

United States

Employees

70

Financials (LTM)

Revenue: $20M
EBITDA: ($69M)

EV

$165M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Orchestra BioMed Financials

Orchestra BioMed reported last 12-month revenue of $20M and negative EBITDA of ($69M).

In the same LTM period, Orchestra BioMed generated $20M in gross profit, ($69M) in EBITDA losses, and had net loss of ($70M).

Revenue (LTM)


Orchestra BioMed P&L

In the most recent fiscal year, Orchestra BioMed reported revenue of $33M and EBITDA of ($51M).

Orchestra BioMed is unprofitable as of last fiscal year, with gross margin of 99%, EBITDA margin of (153%), and net margin of (157%).

See analyst estimates for Orchestra BioMed
LTMLast FY202320242025202620272028
Revenue$20M$33M$3M$3M$33M
Gross Profit$20M$33M$3M$2M$33M
Gross Margin99%99%93%92%99%
EBITDA($69M)($51M)($51M)($64M)($51M)
EBITDA Margin(340%)(153%)(1856%)(2426%)(153%)
EBIT Margin(342%)(155%)(1866%)(2437%)(155%)
Net Profit($70M)($53M)($49M)($61M)($53M)
Net Margin(344%)(157%)(1780%)(2313%)(157%)

Financial data powered by Morningstar, Inc.

Orchestra BioMed Stock Performance

Orchestra BioMed has current market cap of $243M, and enterprise value of $165M.

Market Cap Evolution


Orchestra BioMed's stock price is $4.06.

Orchestra BioMed share price increased by 1.8% in the last 30 days, and by 42.5% in the last year.

Orchestra BioMed has an EPS (earnings per share) of $-0.88.

See more trading valuation data for Orchestra BioMed
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$165M$243M0.0%1.8%-6.4%42.5%$-0.88

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Orchestra BioMed Valuation Multiples

Orchestra BioMed trades at 8.1x EV/Revenue multiple, and (2.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for Orchestra BioMed

EV / Revenue (LTM)


Orchestra BioMed Financial Valuation Multiples

As of May 26, 2026, Orchestra BioMed has market cap of $243M and EV of $165M.

Orchestra BioMed has a P/E ratio of (3.5x).

LTMLast FY202320242025202620272028
EV/Revenue8.1x4.9x59.6x62.4x4.9x
EV/EBITDA(2.4x)(3.2x)(3.2x)(2.6x)(3.2x)
EV/EBIT(2.4x)(3.2x)(3.2x)(2.6x)(3.2x)
EV/Gross Profit8.2x4.9x63.9x67.6x4.9x
P/E(3.5x)(4.6x)(4.9x)(4.0x)(4.6x)
EV/FCF(2.9x)(3.3x)(3.6x)(3.2x)(3.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Orchestra BioMed Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Orchestra BioMed Margins & Growth Rates

Orchestra BioMed decreased revenue by 98% but EBITDA grew by 87% in the last fiscal year.

In the most recent fiscal year, Orchestra BioMed reported gross margin of 99%, EBITDA margin of (153%), and net margin of (157%).

See estimated margins and future growth rates for Orchestra BioMed

Orchestra BioMed Margins

Last FY202420252026202720282029
Gross Margin99%92%99%76%
EBITDA Margin(153%)(2426%)(153%)(17537%)
EBIT Margin(155%)(2437%)(155%)(17615%)
Net Margin(157%)(2313%)(157%)(17451%)
FCF Margin(148%)(1927%)(148%)(12632%)

Orchestra BioMed Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(98%)(4%)1169%(98%)
Gross Profit Growth(99%)(5%)1268%(99%)
EBITDA Growth87%25%(20%)87%
EBIT Growth85%25%(19%)85%
Net Profit Growth81%24%(14%)81%
FCF Growth39%10%(3%)39%

Data powered by FactSet, Inc. and Morningstar, Inc.

Orchestra BioMed Operational KPIs

Orchestra BioMed's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $1.2M for the same period.

Orchestra BioMed's Rule of 40 is (17635%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Orchestra BioMed's Rule of X is (17783%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Orchestra BioMed
LTMLast FY202320242025202620272028
Rule of 40(437%)(17635%)———
Bessemer Rule of X(583%)(17783%)———
Revenue per Employee—$0.5M———
Opex per Employee—$1.2M———
R&D Expenses to Revenue304%174%1225%1623%174%
Opex to Revenue—254%1959%2530%254%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Orchestra BioMed Competitors

Orchestra BioMed competitors include Asterasys, Stratec, OraSure, Affluent Medical, Profound Medical, RxSight, Ascom, Humacyte, Eurobio Scientific and Onward Medical.

Most Orchestra BioMed public comparables operate across Medical Devices, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Asterasys9.0x7.6x27.2x22.0x
Stratec1.3x1.2x9.4x9.0x
OraSure0.7x0.7x(2.0x)(2.1x)
Affluent Medical—393.2x—(12.1x)
Profound Medical13.0x10.2x(5.7x)(6.3x)
RxSight0.3x0.3x(1.3x)(0.9x)
Ascom0.6x0.6x5.2x5.3x
Humacyte122.9x60.1x(11.3x)—

This data is available for Pro users. Sign up to see all Orchestra BioMed competitors and their valuation data.

Start Free Trial

Orchestra BioMed Funding History

Before going public, Orchestra BioMed raised $243M in total equity funding, across 5 rounds.


Orchestra BioMed Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jan-22Series DMedtronic; Perceptive Advisors; RTW Investments; SternAegis; Terumo$110M—Orchestra BioMed is a biomedical company developing bioelectronic therapies and cardiovascular devices, including Atrioventricular Interval Modulation for blood pressure reduction, Virtue Sirolimus AngioInfusion Balloon for artery disease, and Cardiac Neuromodulation Therapy for heart failure. In July 2022, the company announced a strategic collaboration with Medtronic and closed a US$110 million private equity financing led by RTW Investments, with participation from Perceptive Advisors, SternAegis Ventures, and Terumo Corporation, alongside plans to list publicly. RTW Investments, the lead investor, maintained significant involvement post-round, reporting a 19.7% stake (11,942,426 shares) as of February 2026 based on 57,069,462 shares outstanding, up from prior holdings via adjusted pre-funded warrants. RTW's portfolio updates in 2022 highlight Orchestra BioMed's progress amid biotech market challenges, with the company's NAV outperforming indices like Russell 2000 Biotechnology. Orchestra BioMed also made investments, such as a $23M Series D in Vivasure Medical in May 2022.
Jun-19Strategic investmentTerumo$35M—Orchestra BioMed announced a global strategic partnership with Terumo Corporation on June 13, 2019, to develop and commercialize the Virtue sirolimus-eluting balloon (SEB) for treating in-stent restenosis and other coronary and peripheral vascular interventions. The partnership involved a $30 million upfront payment from Terumo plus a $5 million equity investment, along with substantial future clinical and regulatory milestone payments and a strong commitment to finance and execute a global clinical program. Orchestra retained meaningful revenue sharing through royalties and per-unit payments as the exclusive supplier of the sustained-release sirolimus formulation, and retained rights to develop and license the technology for applications outside coronary and peripheral vascular interventions. This strategic partnership was framed as validation of Orchestra's strategy to leverage alliances with established market leaders. Virtue SEB had demonstrated excellent angiographic results at six months and outstanding clinical outcomes extending to three years in prospective studies of challenging in-stent restenosis patients. Orchestra planned to conduct a U.S. registrational trial for in-stent restenosis in the near term following the announcement.
Mar-19Series BKinled Holding; Perceptive Advisors; RTW Investments; Soleus Capital; SternAegis$34M—Orchestra BioMed, a US-based biomedical therapy system developer focused on treatments for artery disease, hypertension, and other diseases with high unmet needs, closed a $34 million Series B1 round in mid-2019 co-led by Perceptive Advisors, RTW Investments, and Soleus Capital, with participation from SternAegis Ventures and Terumo Corporation. Terumo's $5 million equity investment was part of a strategic collaboration that included a $30 million upfront payment for partnership on percutaneous coronary and peripheral vascular interventions. The funds were allocated to accelerate pipeline development, clinical trials, and support the Terumo partnership. The company was eligible for up to an additional $57 million in Series B and B1 funding. This Series B1 followed a $41 million round in November 2018, where SternAegis Ventures acted as placement agent and $23 million of debt converted to equity. Orchestra BioMed's products include therapies like an alternative to drug-coated balloons for artery disease, with Terumo tapped for commercialization. Later developments include a Series D round in 2022 raising $110 million from investors including Medtronic, RTW Investments, Perceptive Advisors, SternAegis Ventures, and Terumo, alongside a SPAC merger valuing the enterprise at $158 million.
Nov-18Undisclosed stage—$41M—Orchestra BioMed, a biomedical innovation company, develops advanced therapeutic solutions for unmet medical needs, including the Virtue Sirolimus-Eluting Balloon for artery disease and BackBeat Cardiac Neuromodulation Therapy for hypertension. On November 15, 2018, it completed a $41 million private equity financing, which was oversubscribed and expanded beyond its target, including conversion of outstanding debt to equity. Proceeds support late-stage clinical development of its lead product candidates in interventional cardiology and electrophysiology markets. SternAegis Ventures served as exclusive placement agent, highlighting the potential of Orchestra BioMed's pipeline and innovative business model adapting biotech strategies to medtech. The round structure incentivizes an additional $23 million in future follow-on capital. The company aims to forge strategic partnerships with global market leaders to optimize clinical impact, commercial penetration, and health-economic value in mature procedure-based markets. Subsequent funding history shows Orchestra BioMed raised a total of $245M over multiple rounds, with later activities including a Series D in 2022 and a reverse merger in January 2023. More recent financings, such as over $111 million in proceeds from public/private offerings and commitments from Ligand and Medtronic, funded clinical programs like the BACKBEAT study and Virtue SAB trial, providing multi-year funding clarity.
Jan-18Undisclosed stageSternAegis$23M—Orchestra BioMed is a biomedical innovation company developing advanced therapeutic solutions for major unmet medical needs, with a business model designed to accelerate high-impact technologies through risk-reward sharing partnerships with leading medical device companies. The company's flagship product candidates include the Virtue Sirolimus-Eluting Balloon (SEB) or Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of artery disease and the BackBeat Cardiac Neuromodulation Therapy (CNT), also known as AVIM Therapy, for the treatment of hypertension. Orchestra BioMed completed a $41 million private equity financing in November 2018, which included the conversion of outstanding debt to equity, with SternAegis Ventures serving as the exclusive placement agent; the offering was fully oversubscribed and expanded beyond its original maximum target. The company later closed a $110 million Series D financing in July 2022, including a $40 million investment from Medtronic, a $20 million investment from RTW Investments, and investments from other existing shareholders including Perceptive Advisors, Terumo Corporation, and SternAegis Ventures. Orchestra BioMed has strategic partnerships with Terumo for the development and commercialization of Virtue SAB and with Ligand Pharmaceuticals, which purchased a $35 million revenue participation right on future AVIM and Virtue SAB revenues, demonstrating investor confidence in the company's pipeline and innovative business model.

Orchestra BioMed Investment Activity

Orchestra BioMed has invested in 1 company to date.

Latest investment by Orchestra BioMed was on May 17th 2022. Orchestra BioMed invested in Vivasure Medical in their $23M Series D round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by Orchestra BioMed

Vivasure Medical
Description
Vivasure Medical is a Galway, Ireland-based developer of the PerQseal vascular closure device for large-bore arteriotomies. The company focuses on minimally invasive solutions for transcatheter aortic valve replacements and endovascular aneurysm repairs. Its collagen plug system achieves immediate hemostasis, reducing complications compared to manual compression. Vivasure Medical has completed European clinical trials and pursues U.S. FDA approval through partnerships with interventional cardiology centers.
HQ CountryIreland
HQ City
Galway
Deal Date17 May 2022
RoundSeries D
Raised$23M
InvestorsEvonik Venture Capital; Fountain Healthcare Partners; LSP Health Economics Fund; Orchestra BioMed; Panakes Partners
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Orchestra BioMed investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Orchestra BioMed

When was Orchestra BioMed founded?Orchestra BioMed was founded in 2018.
Where is Orchestra BioMed headquartered?Orchestra BioMed is headquartered in United States.
How many employees does Orchestra BioMed have?As of today, Orchestra BioMed has over 70 employees.
Who is the CEO of Orchestra BioMed?Orchestra BioMed's CEO is David P. Hochman.
Is Orchestra BioMed publicly listed?Yes, Orchestra BioMed is a public company listed on Nasdaq.
What is the stock symbol of Orchestra BioMed?Orchestra BioMed trades under OBIO ticker.
When did Orchestra BioMed go public?Orchestra BioMed went public in 2023.
Who are competitors of Orchestra BioMed?Orchestra BioMed main competitors include Asterasys, Stratec, OraSure, Affluent Medical, Profound Medical, RxSight, Ascom, Humacyte, Eurobio Scientific, Onward Medical.
What is the current market cap of Orchestra BioMed?Orchestra BioMed's current market cap is $243M.
What is the current revenue of Orchestra BioMed?Orchestra BioMed's last 12 months revenue is $20M.
What is the current revenue growth of Orchestra BioMed?Orchestra BioMed revenue growth (NTM/LTM) is (97%).
What is the current EV/Revenue multiple of Orchestra BioMed?Current revenue multiple of Orchestra BioMed is 8.1x.
Is Orchestra BioMed profitable?No, Orchestra BioMed is not profitable.
What is the current EBITDA of Orchestra BioMed?Orchestra BioMed has negative EBITDA and is not profitable.
What is Orchestra BioMed's EBITDA margin?Orchestra BioMed's last 12 months EBITDA margin is (340%).
What is the current EV/EBITDA multiple of Orchestra BioMed?Current EBITDA multiple of Orchestra BioMed is (2.4x).
What is the current FCF of Orchestra BioMed?Orchestra BioMed's last 12 months FCF is ($57M).
What is Orchestra BioMed's FCF margin?Orchestra BioMed's last 12 months FCF margin is (282%).
What is the current EV/FCF multiple of Orchestra BioMed?Current FCF multiple of Orchestra BioMed is (2.9x).
How many companies Orchestra BioMed has acquired to date?Orchestra BioMed hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Orchestra BioMed has invested to date?As of May 2026, Orchestra BioMed has invested in 1 company.
What was the last Orchestra BioMed investment?On 17th May 2022 Orchestra BioMed invested in Vivasure Medical, participating in a $23M Series D round, alongside Evonik Venture Capital, Fountain Healthcare Partners, LSP Health Economics Fund, and Panakes Partners.
In what companies Orchestra BioMed invested in?Orchestra BioMed invested in Vivasure Medical.

See public comps similar to Orchestra BioMed

Lists including Orchestra BioMed

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial